About Agios Pharmaceuticals
We're focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. Our most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to our active late-stage clinical pipeline, we have multiple novel, investigational therapies in clinical and preclinical development.
We’re a company that cares about our work, each other, and the people who are counting on us the most. We’re inspired to think big and welcome the different perspectives and backgrounds needed to deliver extraordinary results.
|
|
|
501-1,000 employees
View all Agios Pharmaceuticals employees
|
|
Pharmaceuticals
|
|
88 Sidney Street, Cambridge, MA 02139, US
|
|
2008
|
|
Biopharmaceuticals, Rare Genetic Diseases, Cellular Metabolism
|
Agios Pharmaceuticals Alternatives
Frequently Asked Questions about Agios Pharmaceuticals
David Schenkein is the CEO of Agios Pharmaceuticals.
The decision makers in Agios Pharmaceuticals are Brian Goff, Brian Goff, Clive Patience, etc. Click to Find Agios Pharmaceuticals decision makers emails.
Agios Pharmaceuticals Staff Directory
Search Agios Pharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
